Alzheimer's drug trial targets toxic proteases from gum disease bacteria in the brain
The pharmaceutical company, Cortexyme, Inc. has outlined a trial of potential Alzheimer's drug that targets toxic substances released by P. gingivalis, a bacteria linked to gum disease.
Jul 18, 2019
0
8